Arnhold LLC Sells 65,264 Shares of Pfizer Inc. $PFE

Key Points

• Arnhold LLC has reduced its stake in Pfizer Inc. by 8.6%, selling 65,264 shares and now holding 693,482 shares valued at approximately $17.57 million.
• Recently, several analysts adjusted their price targets for Pfizer, with Berenberg Bank lowering it from $28.00 to $25.00, while UBS Group raised theirs from $24.00 to $25.00.
• Pfizer announced a quarterly dividend of $0.43 per share, translating to an annualized dividend yield of 6.7%, with a payout ratio of over 91%.

Arnhold LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 693,482 shares of the biopharmaceutical company's stock after selling 65,264 shares during the period. Pfizer makes up approximately 1.8% of Arnhold LLC's holdings, making the stock its 21st biggest holding. Arnhold LLC's holdings in Pfizer were worth $17,573,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Clarity Asset Management Inc. bought a new position in Pfizer during the 4th quarter worth about $27,000. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the 1st quarter valued at approximately $27,000. Bayforest Capital Ltd bought a new stake in Pfizer in the 1st quarter valued at approximately $28,000. Finally, North Capital Inc. acquired a new position in Pfizer during the 1st quarter worth approximately $28,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on PFE shares. Berenberg Bank lowered their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group boosted their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Wolfe Research raised their price objective on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. Finally, Redburn Atlantic lowered their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Trading Up 1.3%

Shares of NYSE:PFE opened at $25.7060 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $146.15 billion, a P/E ratio of 13.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.52. The company has a 50-day simple moving average of $24.68 and a 200 day simple moving average of $24.42.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer's dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.